[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Dry Eye Syndrome Treatment Market, 2012-2023

January 2018 | 190 pages | ID: D5B518B60B6EN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Dry Eye Syndrome Treatment Market

Dry eye syndrome (keratoconjunctivitis sicca), is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye.

The global dry eye syndrome treatment market is expected to grow at a significant CAGR due to rise in the geriatric population (tear glands weaken due to aging and can’t produce sufficient tear fluid to maintain a lubricating film over the eyes) and increase in the prevalence of dry eye syndrome. The increase in the prevalence of diabetes, vitamin A deficiency, lupus, thyroid disorders, and rheumatoid arthritis might fuel the dry eye syndrome treatment market. Moreover, increasing awareness among the population about diagnosis and treatment of dry eye syndrome, steady government support for medical research has allowed researchers to treat this condition more precisely and comprehensively, external stimuli such as laser eye surgery, and computer screen overuse are key factors also boosting the dry eye syndrome treatment market over the forecast period. However, expiration of blockbuster drug patents, the popularity of self-medication by patients is the major restraints for the dry eye syndrome treatment market over the forecast period.

Dry eye syndrome treatment market segmented on the basis of treatment type, disease type, and distribution channel

Based on treatment type, dry eye syndrome treatment market has been segmented into the following:
  • Lubricant Eye Drops
  • Preservative-Free Drops
  • Oily Tear Eye Drops
  • Eye Ointments
  • Anti-inflammatory Drugs
  • Corticosteroids
  • Tetracyclines Oral
  • Autologous Serum Eye Drops
  • Nutrition supplements
Based on disease type, dry eye syndrome treatment market has been segmented into the following:
  • Evaporative dry eye syndrome
  • Aqueous dry eye syndrome
Based on distribution channel, dry eye syndrome treatment market has been segmented into the following:
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others
Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome. Similarly, in June 2015, Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease. Moreover, in October 2015, Allergan plc launched artificial tear Refresh Optive gel drops to provide artificial tear option to relieve dry eye symptoms.

Geographically, the dry eye syndrome treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the dry eye syndrome treatment market due to high prevalence of lifestyle disorders which increase the chances of contracting dry eye syndrome, increase in the using medications such as antihistamines, pain relievers and antidepressants also increase the risk of dry eye syndrome in North America. Europe holds a dominant share in dry eye syndrome treatment market attributed to increase in the healthcare infrastructure, rise in the R&D activities, and increase in the usage of various medications which reduce the volume of tears produced in the eyes results in dry eye syndrome. Asia-Pacific is an emerging region in dry eye syndrome treatment market owing to increase in population majorly in India and China, strong government support in Asia-Pacific region.

Some of the players in dry eye syndrome treatment market are Novartis AG (Switzerland), Nicox (France), Allergan (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Otsuka Holdings Co., Ltd. (Japan), Auven Therapeutics (U.S.), AFT Pharmaceuticals (New Zealand), I-Med Pharma, Inc. (Canada), Sun Pharmaceuticals Industries Ltd. (India), Mimetogen Pharmaceuticals (U.S.), and Novaliq GMBH (Germany) to name a few.

In March 2017, Novaliq inked an agreement with AFT Pharmaceuticals for the commercialization of NovaTears in New Zealand and Australia

In August 2016, Auven Therapeutics completed the enrollment in confirmatory phase 3 clinical trial of Seciera (OTX-101) for the treatment of dry eye syndrome treatment

In November 2015, Allergan plc inked a licensing agreement with Mimetogen Pharmaceuticals, for the development and commercialization of tavilermide (MIM-D3), a TrkA agonist used in the treatment of dry eye syndrome treatment
1. EXECUTIVE SUMMARY

2. GLOBAL DRY EYE SYNDROME TREATMENT MARKET INTRODUCTION

2.1. Global Dry Eye Syndrome Treatment Market – Taxonomy
2.2. Global Dry Eye Syndrome Treatment Market –Definitions
  2.2.1. Treatment Type
  2.2.2. Disease Type
  2.2.3. Distribution Channel

3. GLOBAL DRY EYE SYNDROME TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Dry Eye Syndrome Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Dry Eye Syndrome Treatment Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Dry Eye Syndrome Treatment Market – Product Pipeline Analysis

4. GLOBAL DRY EYE SYNDROME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL DRY EYE SYNDROME TREATMENT MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Lubricant Eye Drops
  5.1.1. Preservative-Free Drops
    5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.1.3. Market Opportunity Analysis
  5.1.2. Oily Tear Eye Drops
    5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.2.3. Market Opportunity Analysis
  5.1.3. Eye Ointments
    5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.3.3. Market Opportunity Analysis
5.2. Anti-inflammatory Drugs
  5.2.1. Corticosteroids
    5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.1.3. Market Opportunity Analysis
  5.2.2. Tetracyclines Oral
    5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.2.3. Market Opportunity Analysis
5.3. Autologous Serum Eye Drops
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Nutrition supplements
  5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis

6. GLOBAL DRY EYE SYNDROME TREATMENT MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Evaporative Dry Eye Syndrome
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Aqueous Dry Eye Syndrome
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis

7. GLOBAL DRY EYE SYNDROME TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. On-line Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis
7.4. Others
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.4.3. Market Opportunity Analysis

8. GLOBAL DRY EYE SYNDROME TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Dry Eye Syndrome Treatment Market - Opportunity Analysis Index, By Treatment Type, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA DRY EYE SYNDROME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Lubricant Eye Drops
    9.1.1.1. Preservative-Free Drops
    9.1.1.2. Oily Tear Eye Drops
    9.1.1.3. Eye Ointments
  9.1.2. Anti-inflammatory Drugs
    9.1.2.1. Corticosteroids
    9.1.2.2. Tetracyclines Oral
  9.1.3. Autologous Serum Eye Drops
  9.1.4. Nutrition supplements
9.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.2.1. Evaporative Dry Eye Syndrome
  9.2.2. Aqueous Dry Eye Syndrome
9.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  9.3.1. Hospital Pharmacies
  9.3.2. Retail Pharmacies
  9.3.3. On-line Pharmacies
9.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Dry Eye Syndrome Treatment Market - Opportunity Analysis Index, By Treatment Type, Disease Type, By Distribution Channel and Country, 2017 – 2023
9.6. North America Dry Eye Syndrome Treatment Market Dynamics – Trends

10. EUROPE DRY EYE SYNDROME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Lubricant Eye Drops
    10.1.1.1. Preservative-Free Drops
    10.1.1.2. Oily Tear Eye Drops
    10.1.1.3. Eye Ointments
  10.1.2. Anti-inflammatory Drugs
    10.1.2.1. Corticosteroids
    10.1.2.2. Tetracyclines Oral
  10.1.3. Autologous Serum Eye Drops
  10.1.4. Nutrition supplements
10.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Evaporative Dry Eye Syndrome
  10.2.2. Aqueous Dry Eye Syndrome
10.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Hospital Pharmacies
  10.3.2. Retail Pharmacies
    10.3.2.1. On-line Pharmacies
  10.3.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.3.3.1. Germany
    10.3.3.2. UK
    10.3.3.3. France
    10.3.3.4. Spain
    10.3.3.5. Italy
    10.3.3.6. Russia
    10.3.3.7. Poland
    10.3.3.8. Rest of Europe
10.4. Europe Dry Eye Syndrome Treatment Market - Opportunity Analysis Index, Opportunity Analysis Index, By Treatment Type, By Distribution Channel and Country, 2017 – 2023
10.5. Europe Dry Eye Syndrome Treatment Market Dynamics – Trends

11. ASIA-PACIFIC DRY EYE SYNDROME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Lubricant Eye Drops
    11.1.1.1. Preservative-Free Drops
    11.1.1.2. Oily Tear Eye Drops
    11.1.1.3. Eye Ointments
  11.1.2. Anti-inflammatory Drugs
    11.1.2.1. Corticosteroids
    11.1.2.2. Tetracyclines Oral
  11.1.3. Autologous Serum Eye Drops
  11.1.4. Nutrition supplements
11.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Evaporative Dry Eye Syndrome
  11.2.2. Aqueous Dry Eye Syndrome
11.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Hospital Pharmacies
  11.3.2. Retail Pharmacies
    11.3.2.1. On-line Pharmacies
  11.3.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.3.3.1. Japan
    11.3.3.2. China
    11.3.3.3. India
    11.3.3.4. ASEAN
    11.3.3.5. Australia & New Zealand
    11.3.3.6. Rest of Asia-Pacific
11.4. Asia-Pacific Dry Eye Syndrome Treatment Market - Opportunity Analysis Index, By Treatment Type, By Distribution Channel and Country, 2017 – 2023
11.5. Asia Pacific Dry Eye Syndrome Treatment Market Dynamics – Trends

12. LATIN AMERICA DRY EYE SYNDROME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Lubricant Eye Drops
    12.1.1.1. Preservative-Free Drops
    12.1.1.2. Oily Tear Eye Drops
    12.1.1.3. Eye Ointments
  12.1.2. Anti-inflammatory Drugs
    12.1.2.1. Corticosteroids
    12.1.2.2. Tetracyclines Oral
  12.1.3. Autologous Serum Eye Drops
  12.1.4. Nutrition supplements
12.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Evaporative Dry Eye Syndrome
  12.2.2. Aqueous Dry Eye Syndrome
12.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Hospital Pharmacies
  12.3.2. Retail Pharmacies
    12.3.2.1. On-line Pharmacies
  12.3.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.3.3.1. Brazil
    12.3.3.2. Mexico
    12.3.3.3. Argentina
    12.3.3.4. Venezuela
    12.3.3.5. Rest of Latin America
12.4. Latin America Dry Eye Syndrome Treatment Market - Opportunity Analysis Index, By Treatment Type, By Distribution Channel and Country, 2017 – 2023
12.5. Latin America Dry Eye Syndrome Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA DRY EYE SYNDROME TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Lubricant Eye Drops
    13.1.1.1. Preservative-Free Drops
    13.1.1.2. Oily Tear Eye Drops
    13.1.1.3. Eye Ointments
  13.1.2. Anti-inflammatory Drugs
    13.1.2.1. Corticosteroids
    13.1.2.2. Tetracyclines Oral
  13.1.3. Autologous Serum Eye Drops
  13.1.4. Nutrition supplements
13.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Evaporative Dry Eye Syndrome
  13.2.2. Aqueous Dry Eye Syndrome
13.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Hospital Pharmacies
  13.3.2. Retail Pharmacies
    13.3.2.1. On-line Pharmacies
13.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.4.1.1. Gulf Cooperation Council (GCC) Countries
    13.4.1.2. Israel
    13.4.1.3. South Africa
    13.4.1.4. Rest of MEA
13.5. MEA Dry Eye Syndrome Treatment Market - Opportunity Analysis Index, By Treatment Type, By Distribution Channel and Country, 2017 – 2023
13.6. MEA Dry Eye Syndrome Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Novartis AG (Switzerland)
  14.2.2. Nicox (France)
  14.2.3. Allergan (U.S.)
  14.2.4. Santen Pharmaceutical Co., Ltd. (Japan)
  14.2.5. Otsuka Holdings Co., Ltd. (Japan)
  14.2.6. Auven Therapeutics (U.S.)
  14.2.7. AFT Pharmaceuticals (New Zealand)
  14.2.8. I-Med Pharma, Inc. (Canada)
  14.2.9. Sun Pharmaceuticals Industries Ltd. (India)
  14.2.10. Mimetogen Pharmaceuticals (U.S.)
  14.2.11. Novaliq GMBH (Germany)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS


More Publications